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Antibacterial resistance is today a worldwide problem and the demand for new classes of antibacterial
agents with new mode of action is enormous. In the strive for new antibacterial agents that inhibit pilus
assembly, an important virulence factor, routes to introduce triazoles in position 8 and 2 of ring-fused
bicyclic 2-pyridones have been developed. This was made via Sonogashira couplings followed by
Huisgen 1,3-dipolar cycloadditions. The method development made it possible to introduce a diverse
series of substituted triazoles and their antibacterial properties were tested in a whole cell pili-
dependent bioﬁlm assay. Most of the twenty four candidates tested showed low to no activity but
interestingly three compounds, one 8-substituted and two 2-substituted, showed promising activities
with EC50’s between 9 and 50 mM.
 2012 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Considering the ever growing antibiotic resistance developed by
many bacteria, there is an immense need for new compounds with
newmodeof actions, for treatment of bacterial infections. Bicyclic 2-
pyridones, named pilicides, have been designed and synthesized to
inhibit the pili assemblymachinery in uropathogenic Escherichia coli
by inhibition of the chaperone/usher pathway [1]. Furthermore it
has been shown that a carboxylic acid [2,3] or a carboxylic acid
isostere [4] in position 3 is essential for biological activity. Pili are
important virulence factors for the bacteria and they need these
organelles to attach to the host cell, towithstand shear forces (in the
urinary tract), to invade the host and to establish bioﬁlm like colo-
nies [5]. Bacterial bioﬁlms are complex structures and are involved
in many serious bacterial infections such as urinary tract infection
(UTI). UTI by it’s own is responsible for infectingmore than 900 000
womenandmen, several timesperyear inU.S. alone! [6].Depending
on the substitution pattern on the bicyclic 2-pyridones, particularly
in position 8 (Fig. 1), the biological target can be switched from
inhibition of pilus assembly to inhibition of curli formation. In the, Umeå University, Linnaeus
5; fax: þ46 90 7867655.
Almqvist).
nder CC BY-NC-ND license.latter example this is achieved by preventing polymerization of the
major curli subunit protein, CsgA, into a functional amyloid ﬁbre
[2,7]. The bicyclic 2-pyridones are synthesized via an acid induced
acylketene/imine cyclocondensation between an acyl Meldrum’s
acid derivative and a D2-thiazoline, either via conventional heating
[8] or more convenient under microwave irradiation to yield the 7
and 8 substituted bicyclic 2-pyridones [9] (Fig. 1).
Previous biological data has revealed that small heterocycles i.e.
thiophenes and furanes can be beneﬁcial substituents in position 8
(1) and 2 (2) of the ring-fused bicyclic 2-pyridones (Fig. 2), resulting
in increased biological activity [6,10].
These results encouraged us also to investigate other small
heterocycles like triazoles, which ultimately would allow the intro-
duction of a diverse set of substituted heterocycles to gain further
knowledge in structure activity relationships. Substituted triazoles
are scarcely commercially available as their boronic acid/ester coun-
terparts,which considerably limit theSuzukieMiyaura coupling asan
alternative for library synthesis in this case. However, triazoles can be
synthesized via the Huisgen 1,3-dipolar cycloaddition often referred
to as “click chemistry”. This reaction allows late introduction of
diverse substituents, which is advantageous in library synthesis. Tri-
azoles are widely used as mimetics in different occasions, most well
known as peptide bond mimetics [11] but they have also served as
double bond- [12] and furan substitutes [13].
Fig. 1. Schematic view over the acylketene/imine cyclocondensation to the 7- and 8
substituted thiazolino ring-fused bicyclic 2-pyridones. Reaction conditions: (a) TFA,
DCM, MWI 140 C for 2 min.
Fig. 2. Examples of biologically active, heterocycle functionalized bicyclic 2-pyridones,
the heterocycles are highlighted in red. Their respective effective concentration with
50% inhibition (EC50) of pilus dependent bioﬁlm formation is shown. (For interpreta-
tion of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
A
B
Fig. 3. Retrosynthetic scheme over the triazole functionalizations of position 8 (A) and
2 (B).
C. Bengtsson et al. / European Journal of Medicinal Chemistry 54 (2012) 637e646638The halogenated compounds 3 and 4 have previously been
synthesized and successfully used in Pd-catalyzed cross couplings
(i.e. SuzukieMiyaura [14], and Sonogashira couplings [15]). TheseTable 1
Selective Sonogashira coupling of the bromo-iodo-bicyclic 2-pyridone 3 followed by Hui
R X
H N3a
Me I
Et I
cPrCH2 Br
Bn Br
pMeBn Br
pNO2Bn Br
N3b
N3
a TMSN3 was used in the reaction instead of NaN3.
b The azido alcohol was made from the corresponding commercial available amino alccompounds were considered to be key intermediates for the
introduction of substituted triazoles in the 8- and 2 positions
respectively as outlined in the retrosynthetic scheme (Fig. 3).sgen 1,3-dipolar cycloadditions.
Product Yield (%)
6a 42
6b 79
6c 78
6d 54
6e 70
6f 82
6g 84
6h 66
6i 95
ohol via a diazo-transfer reaction with TfN3 according to published procedures [16].
Table 2
Hydrolysis of the 8-position triazole functionalized bicyclic 2-pyridones followed by reductive dehalogenation.
R Product Yield (%) EC50a (mM) Product Yield (%) EC50a (mM)
H 7a 72 >200 8a 73 >200
Me 7b 73 >200 8b 85 >200
Et 7c 87 >200 8c 69 >200
cPrCH2 7d 93 >200 8d 72 >200
Bn 7e 85 100 8e 67 100
pMeBn 7f 82 200 8f 92 75
pNO2Bn 7g 63 35 8gb 82 >200
7h 77 150 8h 88 >200
7i 79 >200 8i 74 >200
a Experiments were performed in triplicates and compared to DMSO-treated controls. The bioﬁlm formation was studied under type-1 pili inducing conditions [5a].
b The nitro group was reduced to the corresponding aniline.
C. Bengtsson et al. / European Journal of Medicinal Chemistry 54 (2012) 637e646 6392. Results and discussion
2.1. Functionalization of the 8-position
Triazole functionalization of the 8-position started by a regio-
selective Sonogashira coupling on the 6-bromo-8-iodo bicyclic 2-
pyridone 3 [14] with trimethylsilylacetylene (TMSA). The trime-
thylsilyl (TMS) group was then deprotected by K2CO3 in THF:MeOH
1:4 to give the terminal acetylene 5 in 76% yield. The terminal
alkyne was then exposed to a Cu(I) catalyzed Huisgen 1,3-dipolar
cycloaddition with a variety of azides (either as presynthesized
azides or by in situ generation via NaN3 and alkyl halides) (Table 1).
LiOH mediated hydrolysis furnished the 6-bromo substituted
carboxylic acid intermediates 7aei in 63e93% yields (Table 2). The
following dehalogenation by ammoniumformate and Pd/C in
reﬂuxing methanol [14] gave the ﬁnal 8-triazole functionalized
bicyclic 2-pyridones 8aei in 67e92% yields (Table 2) without any
debenzylation detected (i.e. 8f and 8g, Table 2).
The compounds (7ae7i and 8ae8i) were evaluated for their
ability to inhibit the formation of pili in an uropathogenic E. coli
strain (the clinical isolate UTI89). The assay is a whole cell based
assay where the bacteria are grown under conditions where they
form a bacterial bioﬁlm, which is dependent upon pilus assembly.
The efﬁcacy as a whole of the compounds is not only dependent on
there direct interaction with the target (Chaperone-Usher
pathway) but also upon their ability to enter the bacteria. Hence, it
is hard to foresee and predict if a substitution pattern will be goodor bad for antibacterial activity. In the series of 8-triazolo
substituted pilicides only ﬁve out of eighteen tested compounds
had an activity with an EC50 below 200 mM (i.e. 7e, 7g, 7h, 8e and
8f). However, the best pilicide in this collection, 7g, was active in
the lower mM range (EC50 at 35 mM), which is comparable to the
thiophene analogue 1 with an EC50 of 39 mM. Interestingly, the
analogues most similar to pilicide 1 in size (i.e. 8a and 8b) both had
EC50’s higher than 200 mM.
2.2. Functionalization of the 2-position
Triazole functionalization of the 2-position turned out to be
more demanding. Our ﬁrst attempt was made with the previously
published alkyne functionalized bicyclic 2-pyridone methyl ester 9
[15]. The Huisgen 1,3-dipolar cycloaddition proceeded in 71%,
however the methyl ester 10 was shown to be very difﬁcult to
hydrolyze and only generated the decarboxylated compound 11,
even when using the hydrolysis method previously developed for
thiophene and furane substituted compounds (i.e. 2) (Scheme 1).
The starting material was exchanged for the corresponding
alkyne functionalized trimethylsilyl ethyl ester (TMSE) 12 [15],
which can be deprotected under milder conditions. Due to higher
lipophilicity of these compounds DMSO:H2O 1:1 could not be used
as solvent for the Huisgen 1,3-dipolar cycloaddition. Instead the
DMSO content was increased to DMSO:H2O 9:1 and after subse-
quent TBAF$3H2O deprotection of the TMSE ester in THF at room
temperature the 2-position triazole functionalized bicyclic 2-
Scheme 1. Synthesis of triazole substituted methyl ester and attempted hydrolysis.
Reaction conditions: (a) CuSO4, Na-ascorbate, NaN3, MeI, DMSO:H2O 1:1, 71%.
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steps (Table 3) without any decarboxylation detected.
Four out of six analogues showed 50% effective concentrations
lower than 200 mM (Table 3). As pointed out earlier, the assay in this
case is a whole cell assay, which will reﬂect not only the direct
interaction with the potential target but also will take into account
uptake anddistributionwithin the bacteria, a clear structure activity
can be hard to predict. The trend is that a larger substituent in
position eight (e.g. R¼mCF3Ph) is better than a smaller (e.g. R¼ cPr)
but interestingdifferences canbe seenwhen the triazolo substituent
is taken into account. Here R1 ¼ H is better in combination with
a cyclopropyl substituent compared to a meta CF3-phenyl substit-
uent (compare 13a with 13d) and the opposite is seen for R1 ¼ Bn
(compare13cwith13f). Pilicide13ewas themostpotent analogue in
this study and had an EC50 of 9 mM,which is very promising. Among
the pilicides tested the past two years (approx. 120) [6,10,17] only
sixteen of them have shown EC50 below 10 mMwith the best being
a pilus dependent bioﬁlm inhibitor with an EC50 of 400 nM [10].Table 3
Huisgen 1,3-dipolar cycloaddition in position 2 of the thiazolo ring-fused bicyclic 2-pyri
Product R R1
13a cPr H
13b cPr Me
13c cPr Bn
13d mCF3Ph H
13e mCF3Ph Me
13f mCF3Ph Bn
a Approx 5% of 13a was formed.
b Approx 10% of 13a was formed.
c Approx 5% of 13d was formed.
d CuTC was used instead of CuSO4/Na-ascorbate.
e Approx 10% of 13d was formed.
f Experiments were performed in triplicates and compared to DMSO-treated controls3. Conclusion
Herein we present a synthetic route to functionalize the ring-
fused bicyclic 2-pyridones in position 8 and 2 with triazoles. This
was made via a Sonogashira coupling followed by a Huisgen 1,3-
dipolar cycloaddition. In the 8-position this strategy was effective
for a wide range of azides, both in situ generated (6beg),
commercially available (6a and 6i) and synthesized (6h). The 2-
position triazole functionalized methyl ester was proven to be
hard to hydrolyze this problem was circumvented by using the
previously developed TMSE esters 12aeb [15], which could be
deprotected under mild conditions with TBAF in THF at room
temperature without any decarboxylation observed. All together
this gave a collection of twenty-four potential pilus dependent
bioﬁlm inhibitors. The evaluation showed that the 8-position was
difﬁcult to vary without affecting the bioﬁlm inhibition capacity
negatively. Here only one out of eighteen pilicides gave an EC50
below 50 mM. However, in the 2 position it was shown that
substituted triazoles can be a very attractive substituent for the
future, with the best pilicide 13e showing EC50 values below 10 mM.
Both small (methyl, 13e) and larger (benzyl, 13f) groups in the tri-
azolo substituent were allowed indicating that further ﬁne-tuning
of the substitution pattern in this position have potential to result
in more potent pilicides. The methodologies developed in this
study are general and robust, which is a prerequisite to enable such
studies in the future.
4. Experimental section
4.1. General synthesis
Unless stated otherwise, all reagents and solvents were used as
received from commercial suppliers. CuI was puriﬁed by reﬂuxing
with DCM for 20 h in a Soxhlet apparatus and stored under dark and
dry conditions. DMFwas distilled under vaccum and stored over 3 Ådones followed by TBAF deprotection of the TMSE ester.
X Yield (%) EC50 (mM)f
56 75
I 69a 150
Br 54b >200
61 >200
I 61c,d 9
Br 55e 50
. The bioﬁlm formation was studied under type-1 pili inducing conditions [5a].
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columnwith H2O:MeCN mixtures as eluent. TLC was performed on
silica gel detected with UV-light. Column chromatography was
employed on normal phase silica gel (eluents given in brackets).
Optical rotation was measured with a polarimeter at 20 C and
589 nm. IR was recorded on a spectrometer equipped with an ATR
device. 1H and 13C NMR spectra were recorded on a 400 MHz or
a 500 MHz spectrometer at 298 K and calibrated using the residual
peak of solvent as internal standard [CDCl3 (CHCl3 dH 7.26 ppm,
CDCl3 dC 77.16 ppm), d6-DMSO (d5-DMSO dH 2.49 ppm, d6-DMSO dC
39.5 ppm), d3-AcOD (d2-AcOD dH 2.00 ppm and 11.70 ppm, d3-AcOD
dC 20.0 ppm and 180.0 ppm)]. HRMS was performed using a mass
spectrometer with electrospray ionization (ESþ), sodiumformate
was used as calibration chemical. E. coli, UTI89, was inoculated in LB
over night at 37 C. The next day the culturewas diluted 1:1000 in LB
andplated into 96-well PVC plates (Falcon#353911),100 ml perwell.
Compounds were added to the wells to desired concentration, the
DMSO concentration was kept constant. The plates were incubated
for 24h in humid boxes at 26 C. The plateswerewashed extensively
with water and air dried before 125 ml/well of 1% crystal violet
(Sigma C3886) was added. The plates were incubated with crystal
violet for 10 min at room temperature, washed extensively with
water and then air dried. 150 ml/well of 33% acetic acid was added,
100 ml fromeachwell was transferred to a newclear bottom96-well
plates (Nunc #167008). Absorbance was read at 600 nm. Growth
was monitored in separate sterile clear bottom 96-well plates. All
experiments were performed in triplicates.
Compounds 3 [14], 4 [6], 9 [15] and 12 [15] were synthesized
according to published procedures. Data in agreement with pub-
lished data.
4.1.1. (3R)-6-Bromo-7-naphthalen-1-ylmethyl-5-oxo-8-ethynyl-2,3-
dihydro-5H-thiazolo[3,2-a]pyridine-3-carboxylic acidmethyl ester (5)
3 (1.5 g, 2.7 mmol), CuI (51.4 mg, 0.27 mmol), Pd(PPh3)2Cl2
(94.7 mg, 0.135 mmol) and TEA (0.75 ml, 5.4 mmol) in DMF (25 ml,
degassed before use) was stirred for 5 min and TMSA (1.14 ml,
8.1 mmol) in DMF (7 ml) was added dropwise over 5 min. The ﬂask
was sealed and stirred at room temperature under nitrogen
atmosphere for 20 h. The reaction mixture was diluted with EtOAc
and washed with brine. The organic layer was dried (Na2SO4),
ﬁltered and concentrated. The crude material was dissolved in THF/
MeOH 1:4 (70 ml) and K2CO3 (746 mg, 5.4 mmol) was added, the
reaction was stirred at room temperature for 15 min. The reaction
mixture was diluted with EtOAc and washed with brine. The
organic layer was dried (Na2SO4), ﬁltered and concentrated. Puri-
ﬁcation by column chromatography on silica gel (Heptane:EtOAc
65:35) gave 5 (931 mg, 76%). [a]D 1 (c 0.50, CHCl3); IR 3226, 2952,
2361, 1747, 1642, 1576, 1473, 1212, 999, 771 cm1; 1H NMR,
(400 MHz, CDCl3) d 8.13 (d, J ¼ 8.8 Hz, 1H), 7.89 (d, J ¼ 8.8 Hz, 1H),
7.75 (d, J¼ 8.8 Hz, 1H), 7.62e7.57 (m,1H), 7.56e7.51 (m,1H), 7.35 (t,
J ¼ 7.6 Hz, 1H), 6.94 (dd, J ¼ 7.2, 0.8 Hz, 1H), 5.74 (dd, J ¼ 8.8, 2.4 Hz,
1H), 4.69 (s, 2H), 3.87 (s, 3H), 3.85e3.81 (m, 1H), 3.62 (dd, J ¼ 12.0,
2.4 Hz, 1H), 3.15 (s, 1H); 13C NMR (100 MHz, CDCl3) d 167.9, 157.2,
153.4, 152.8, 133.9, 132.0, 131.8, 129.0, 127.4, 126.3, 125.9, 125.7,
124.0, 123.1, 113.7, 98.4, 85.3, 65.4, 53.8, 38.0, 32.0; LRMS (ES) calcd
[M þ H] for C22H17BrNO3S 455, obsd 455.
4.2. Typical procedure for the Huisgen 1,3-dipolar cycloaddition in
the 8-position (compounds 6aei)
4.2.1. (3R)-6-Bromo-8-(1-methyl-1H-[1,2,3]triazol-4-yl)-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid methyl ester (6b)
NaN3 (25.8 mg, 0.40 mmol), Na-ascorbate (5.9 mg, 0.03 mmol)
and CuSO4 (1.6 mg, 0.01 mmol) were dissolved in water (0.75 ml).The mixture was stirred for 5 min at room temperature and DMF
(0.75 ml), MeI (6 ml, 0.10 mmol) and 5 (30 mg, 0.066 mmol) were
added. The reaction mixture was stirred at 70 C for 16 h (oil bath).
Diluted with EtOAc and washed with brine. The organic layer was
dried (Na2SO4), ﬁltered and concentrated. The crude product was
puriﬁed by column chromatography on silica gel (heptane:EtOAc
80:20/ 0:100) gave 6b (26.6 mg, 79%).[a]D 0 (c 0.50, CDCl3); IR
1740, 1652, 1472, 1212, 988, 792 cm1; 1H NMR, (400 MHz, CHCl3)
d 7.89e7.80 (m, 2H), 7.75 (d, J ¼ 8.3 Hz, 1H), 7.54e7.49 (m, 2H), 7.35
(t, J ¼ 7.5 Hz, 1H), 7.03 (dd, J ¼ 7.1, 0.9 Hz, 1H), 6.64 (s, 1H), 5.76 (dd,
J ¼ 8.6, 2.5 Hz, 1H), 4.57e4.40 (m, 2H), 3.86 (s, 3H), 3.74e3.67 (m,
4H), 3.53 (dd, J ¼ 11.8, 2.5 Hz, 1H); 13C NMR (100 MHz, CDCl3)
d 168.2, 157.6, 152.0, 148.6, 142.1, 133.8, 132.7, 131.5, 128.9, 127.5,
126.5, 126.1, 125.7, 124.7, 123.7, 123.0, 114.8, 106.5, 64.9, 53.7,
37.4, 36.7, 31.9; LRMS (ES) calcd [M þ H] for C23H20BrN4O3S
512, obsd 512.
4.2.2. (3R)-6-Bromo-7-naphthalen-1-ylmethyl-5-oxo-8-(1H-[1,2,3]
triazol-4-yl)-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-carboxylic
acid methyl ester (6a)
From 5 (40 mg, 0.088 mmol) was prepared 6a (19 mg, 42%
yield) after puriﬁcation by column chromatography on silica gel
heptane:EtOAc 30:70; [a]D 1 (c 0.50, DMSO); IR 2355, 1744,
1622, 1473, 1155, 975, 792; 1H NMR, (400 MHz, d6-DMSO)
d 8.08e8.01 (m, 1H), 7.97e7.91 (m, 1H), 7.79 (d, J ¼ 8.3 Hz, 1H),
7.59e7.51 (m, 2H), 7.40 (t, J ¼ 7.7 Hz, 1H), 7.24 (s, 1H), 6.92 (d,
J ¼ 7.2 Hz, 1H), 5.77 (dd, J ¼ 10.4, 1.7 Hz, 1H), 4.57e4.36 (m, 2H),
3.87 (dd, J ¼ 12.1, 9.4 Hz, 1H), 3.80 (s, 3H), 3.56 (dd, J ¼ 12.1,
1.6 Hz, 1H); 13C NMR (100 MHz, d6-DMSO) d 168.5, 156.3, 151.1,
148.7, 139.7, 133.3, 132.6, 131.1, 128.7, 128.6, 126.8, 126.3, 125.9,
125.5, 123.6, 123.1, 113.0, 107.1, 64.4, 53.1, 37.1, 30.9; LRMS (ES)
calcd [M þ H] for C22H18BrN4O3S 498, obsd 498.
4.2.3. (3R)-6-Bromo-8-(1-ethyl-1H-[1,2,3]triazol-4-yl)-7-naphthalen-
1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid methyl ester (6c)
From 5 (100 mg, 0.22 mmol) was prepared 6c (90 mg, 78%
yield) after puriﬁcation by column chromatography on silica gel
heptane:EtOAc 80:20 / 0:100; [a]D 2 (c 0.50, CHCl3); IR 1747,
1646, 1472, 1213, 1174, 792 cm1; 1H NMR, (400 MHz, CDCl3)
d 7.89e7.79 (m, 2H), 7.74 (d, J ¼ 8.2 Hz, 1H), 7.53e7.46 (m, 2H),
7.35 (t, J ¼ 8.0 Hz, 1H), 7.04 (d, J ¼ 7.1 Hz, 1H), 6.54 (s, 1H), 5.76
(dd, J ¼ 8.5, 2.3 Hz, 1H), 4.55e4.39 (m, 2H), 3.97 (dq, J ¼ 2.1,
8.5 Hz, 2H), 3.86 (s, 3H), 3.71 (dd, J ¼ 11.8, 8.6 Hz, 1H), 3.52 (dd,
J ¼ 11.8, 2.4 Hz, 1H), 0.97 (t, J ¼ 7.4 Hz, 3H); 13C NMR (100 MHz,
CDCl3) d 168.2, 157.6, 152.1, 148.6, 141.8, 133.9, 132.7, 131.4, 128.9,
127.5, 126.5, 126.1, 125.7, 124.7, 123.0, 122.1, 114.9, 106.5, 64.9,
53.7, 45.2, 37.5, 31.9, 14.7; LRMS (ES) calcd [M þ H] for
C24H22BrN4O3S 526, obsd 526.
4.2.4. (3R)-6-Bromo-8-(1-cyclopropylmethyl-1H-[1,2,3]triazol-4-
yl)-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid methyl ester (6d)
From 5 (40 mg, 0.088 mmol) was prepared 6d (26 mg, 54%
yield) after puriﬁcation by column chromatography on silica gel
heptane:EtOAc 80:20 / 0:100; [a]D 1 (c 0.50, CHCl3); IR 1738,
1646, 1472, 1432, 1212, 1170, 791 cm1; 1H NMR, (400 MHz,
CDCl3) d 7.90e7.83 (m, 2H), 7.76 (d, J ¼ 8.2 Hz, 1H), 7.53e7.47
(m, 2H), 7.37 (t, J ¼ 7.6 Hz, 1H), 7.05 (d, J ¼ 6.9 Hz, 1H), 6.71
(s, 1H), 5.78 (dd, J ¼ 8.5, 2.2 Hz, 1H), 4.58e4.41 (m, 2H), 3.87 (s,
3H), 3.85e3.75 (m, 2H), 3.75e3.67 (m, 1H), 3.54 (dd, J ¼ 11.8,
2.3 Hz, 1H), 0.61e0.50 (m, 1H), 0.19e0.06 (m, 2H), 0.12e0.19
(m, 2H); 13C NMR (100 MHz, CDCl3) d 168.2, 157.6, 151.6,
148.5, 141.7, 134.0, 132.5, 131.4, 128.9, 127.5, 126.6, 126.1, 125.8,
124.6, 123.0, 122.1, 115.0, 106.7, 64.9, 54.9, 53.7, 37.8, 32.0, 10.2,
C. Bengtsson et al. / European Journal of Medicinal Chemistry 54 (2012) 637e6466423.8, 3.7; LRMS (ES) calcd [M þ H] for C26H24BrN4O3S 552,
obsd 552.
4.2.5. (3R)-8-(1-Benzyl-1H-[1,2,3]triazol-4-yl)-6-bromo-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid methyl ester (6e)
From 5 (40 mg, 0.088mmol) was prepared 6e (36 mg, 70% yield)
after puriﬁcation by column chromatography on silica gel hepta-
ne:EtOAc 90:10/ 20:80; [a]D 4 (c 0.25, DMSO); IR 1750, 1646,
1598, 1474, 1212, 792, 725 cm1; 1H NMR, (400 MHz, d6-DMSO)
d 8.03e7.93 (m, 2H), 7.83 (s, 1H), 7.78 (d, J ¼ 8.2 Hz, 1H), 7.57e7.53
(m, 2H), 7.36 (t, J ¼ 7.4 Hz, 1H), 7.17 (t, J ¼ 7.2 Hz, 1H), 7.05 (t,
J¼ 7.3 Hz, 2H), 6.88 (d, J¼ 7.1 Hz,1H), 6.77 (t, J¼ 7.7 Hz, 2H), 5.79 (d,
J ¼ 9.0 Hz, 1H), 5.40 (s, 2H), 4.58e4.34 (m, 2H), 3.95e3.86 (m, 1H),
3.79 (s, 3H), 3.65e3.58 (m, 1H); 13C NMR (100 MHz, d6-DMSO)
d 168.4, 156.4, 151.3, 149.7, 141.2, 135.5, 133.2, 132.1, 131.0, 128.6,
128.5 (2C), 127.8, 126.9, 126.9 (2C), 126.3, 125.9, 125.5, 124.3, 123.6,
123.0, 113.1, 105.3, 64.5, 53.2, 52.6, 36.8, 31.1; LRMS (ES) calcd
[M þ H] for C29H24BrN4O3S 588, obsd 588.
4.2.6. (3R)-6-Bromo-8-[1-(4-methyl-benzyl)-1H-[1,2,3]triazol-4-
yl]-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid methyl ester (6f)
From 5 (60 mg, 0.132 mmol) was prepared 6f (65 mg, 82% yield)
after puriﬁcation by column chromatography on silica gel hepta-
ne:EtOAc 85:15/ 0:100; [a]D 1 (c 0.50, CHCl3); IR 1748, 1645,1472,
1212, 1156, 792, 770 cm1; 1H NMR, (400 MHz, CDCl3) d 7.89 (dd,
J ¼ 9.2, 1.3 Hz, 1H), 7.80 (d, J ¼ 8.2 Hz, 1H), 7.71 (d, J ¼ 8.2 Hz, 1H),
7.57e7.47 (m, 2H), 7.26 (t, J¼ 7.7Hz,1H), 6.94 (dd, J¼ 8.0, 0.9Hz,1H),
6.85 (d, J¼ 7.8 Hz, 2H), 6.61 (d, J¼ 8.0 Hz, 2H), 6.55 (s, 1H), 5.75 (dd,
J ¼ 8.6, 2.4 Hz, 1H), 5.1 (s, 2H), 4.53e4.35 (m, 2H), 3.85 (s, 3H), 3.69
(dd, J¼11.8, 8.6Hz,1H), 3.51 (dd, J¼11.8, 2.4Hz,1H), 2.27 (s, 3H); 13C
NMR (100MHz, CDCl3) d 168.1,157.5,151.7, 148.4,142.0,138.5,133.8,
132.3, 131.3, 130.5, 129.6 (2C), 128.9, 127.9 (2C), 127.4, 126.5, 126.0,
125.6,124.4,123.0,122.6,114.9,106.5, 64.8, 53.9, 53.7, 37.6, 31.9, 21.2;
LRMS (ES) calcd [M þ H] for C30H26BrN4O3S 603, obsd 603.
4.2.7. (3R)-6-Bromo-7-naphthalen-8-[1-(4-nitro-benzyl)-1H-
[1,2,3]triazol-4-yl]-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-
a]pyridine-3-carboxylic acid methyl ester (6g)
From 5 (40 mg, 0.088mmol) was prepared 6g (49 mg, 84% yield)
after puriﬁcation by column chromatography on silica gel hepta-
ne:EtOAc 80:20/ 0:100; [a]D 1 (c 0.50, CHCl3); IR 1747, 1644, 1416,
1472, 1342, 1213, 725 cm1; 1H NMR, (400 MHz, CDCl3) d 7.88e7.81
(m, 3H), 7.76 (d, J¼ 8.3 Hz,1H), 7.68 (d, J¼ 8.3 Hz,1H), 7.57e7.44 (m,
2H), 7.26 (t, J¼ 7.7 Hz,1H), 6.95 (d, J¼ 7.1 Hz,1H). 6.78 (d, J¼ 8.8 Hz,
2H), 6.64 (s, 1H), 5.76 (dd, J ¼ 8.6, 2.4 Hz, 1H), 5.30e5.19 (m, 2H),
4.52e4.33 (m, 2H), 3.86 (s, 3H), 3.73 (dd, J ¼ 11.8, 8.6 Hz, 1H), 3.54
(dd, J ¼ 11.8, 2.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) d 168.1, 157.5,
151.3, 148.6, 147.9, 142.7, 140.5, 133.8, 132.1, 131.2, 128.9, 128.3 (2C),
127.5, 126.6, 126.3, 125.6, 124.2 (2C), 124.2, 122.9, 122.8, 115.0, 105.9,
64.8, 53.7, 53.0, 37.7, 32.0; LRMS (ES) calcd [M þ H] for
C29H23BrN5O5S 633, obsd 633.
4.2.8. (3R)-8-((S)-1-Benzyl-2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-
yl)-6-bromo-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-
thiazolo[3,2-a]pyridine-3-carboxylic acid methyl ester (6h)
From 5 (100mg, 0.22mmol) was prepared 6h (92mg, 66% yield)
after puriﬁcation by column chromatography on silica gel hepta-
ne:EtOAc 75:25/ 0:100; [a]D 222 (c 0.10, DMSO); IR 1744, 1636,
1591,1475,1220,1158, 987, 791 cm1; 1HNMR, (400MHz, d6-DMSO)
d 8.11e7.99 (m,1H), 7.98e7.90 (m,1H), 7.87e7.77 (m, 2H), 7.64e7.52
(m, 2H), 7.45e7.37 (m, 1H), 7.02e6.84 (m, 4H), 6.75e6.66 (m, 2H),
5.84e5.77 (m,1H), 5.04 (s,1H, broad), 4.67e4.24 (m, 3H), 3.95e3.84
(m,1H), 3.84 (s, 3H), 3.66e3.53 (m, 3H), 3.05e2.64 (m, 2H); 13CNMR(100 MHz, d6-DMSO) d 168.4 (splitted, 1C), 156.4, 151.5 þ 151.4 (1C),
149.6, 140.8 þ 140.6 (1C), 136.9, 133.3 (splitted, 1C), 132.5 (splitted,
1C),131.1 (splitted,1C),128.6 (splitted,1C),128.5 (splitted,1C),128.5
(splitted, 1C), 128.1 (splitted, 2C), 126.8 (splitted, 1C), 126.3 þ 126.2
(2C), 125.9 (splitted, 1C), 125.5 (splitted, 1C), 123.8 (splitted, 1C),
123.3 þ 123.1 (1C), 123.1 þ 122.9 (1C), 113.0 þ 113.0 (1C),
105.8þ 105.7 (1C), 64.6þ 64.5 (2C), 62.8 þ 62.7 (1C), 53.1 (splitted,
1C), 36.9 (splitted, 1C), 36.6 þ 36.5 (1C), 31.1 þ 31.0 (1C); LRMS (ES)
calcd [M þ H] for C31H28BrN4O4S 633, obsd 633.
4.2.9. (3R)-6-Bromo-7-naphthalen-1-ylmethyl-5-oxo-8-[1-(2,3,4-
tri-O-acetyl-ß-D-xylopyranosyl)-1H-[1,2,3]triazol-4-yl]-2,3-dihydro-
5H-thiazolo[3,2-a]pyridine-3-carboxylic acid methyl ester (6i)
From5 (50mg,0.11mmol)wasprepared6i (79mg,95%yield) after
puriﬁcation by column chromatography on silica gel heptane:EtOAc
85:15/0:100; [a]D2 (c0.50, CHCl3); IR1740,1646,1473,1365,1207,
1033, 746 cm1; 1H NMR, (400MHz, CDCl3) d 8.04e7.84 (m, 2H), 7.76
(t, J ¼ 7.8 Hz, 1H), 7.59e7.46 (m, 2H), 7.38e7.32 (m, 1H), 7.02 (t,
J ¼ 7.1 Hz, 1H), 6.97, 6.86 (s, 1H), 5.79e5.71 (m, 1H), 5.45 (dd, J ¼ 8.9,
6.3 Hz,1H), 5.22 (dt, J¼ 9.4,1.1 Hz,1H), 4.85e4.62 (m, 2H), 4.58e4.35
(m, 2H), 3.98e3.87 (m, 1H), 3.84, 3.83 (s, 3H), 3.76e3.64 (m, 1H),
3.54e3.48 (m,1H), 3.38e3.28 (m,1H), 2.05e1.97 (m, 6H),1.71,1.59 (s,
3H); 13C NMR (100 MHz, CDCl3) d 169.7 (splitted, 1C), 169.7,
168.8þ 168.7 (1C),168.1þ168.0 (1C),157.5þ157.4 (1C),151.9þ151.6
(1C), 148.8 þ 148.6 (1C), 142.6 þ 142.5 (1C), 134.0 þ 133.9 (1C),
132.3þ132.2 (1C),131.4þ131.3 (1C),129.0þ128.9 (1C),127.6þ127.5
(1C), 126.5 þ 126.4 (1C), 126.1 þ 125.9 (1C), 125.8 þ 125.7 (1C),
124.5þ124.4 (1C),123.4þ123.2 (1C),121.3þ121.0 (1C),115.2þ114.9
(1C),106.0þ 105.8 (1C), 86.3þ 86.2 (1C), 71.4þ71.3 (1C), 70.9þ 70.4
(1C), 68.2 þ 68.1 (1C), 65.2, 65.0 þ 64.7 (1C), 53.6 (splitted, 1C),
37.3þ 37.2 (1C), 32.0 þ 31.9 (1C), 20.7, 20.6 (splitted, 1C), 20.0þ 19.8
(1C); LRMS (ES) calcd [M þ H] for C33H32BrN4O10S 757, obsd 757.
4.3. Typical procedure for hydrolysis of the 8-position triazole
functionalized bicyclic 2-pyridones (compounds 7aei)
4.3.1. (3R)-6-Bromo-7-naphthalen-1-ylmethyl-5-oxo-8-(1H-[1,2,3]
triazol-4-yl)-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-carboxylic
acid (7a)
6a (29.0 mg, 0.058 mmol) was dissolved in THF (5 ml) and 1 M
LiOH (0.174 ml) was added. The mixture was stirred at room
temperature for 17 h. The suspension was diluted with EtOAc and
brinewas added.1MHCl was added until pH¼ 1. The organic phase
was dried (Na2SO4), ﬁltered and concentrated. Puriﬁcation by HPLC
gave 7a (20.1 mg, 72%). [a]D 1 (c 0.10, DMSO); IR 2936, 1722, 1619,
1472,1390,1158,1139, 977, 792 cm1; 1HNMR, (400MHz, d6-DMSO)
d 15.05 (broad s, 1H), 8.05e7.99 (m, 1H), 7.97e7.91 (m, 1H), 7.79 (d,
J¼ 8.2 Hz, 1H), 7.58e7.53 (m, 2H), 7.40 (t, J¼ 7.4 Hz, 1H), 7.33 (s, 1H,
broad), 6.93 (d, J¼6.9Hz,1H), 5.68 (dd, J¼9.0,1.3Hz,1H), 4.55e4.32
(m, 2H), 3.89 (dd, J¼ 11.9, 9.3 Hz, 1H), 3.59 (dd, J¼ 11.9, 4.7 Hz, 1H);
13C NMR (100 MHz, d6-DMSO) d 169.2, 156.4, 150.8 (broad), 149.6,
141.6 (broad), 133.3, 132.7 (broad), 132.4, 131.0, 128.6, 126.9, 126.4,
125.9, 125.5, 123.7, 123.0, 113.3, 105.2 (broad), 64.7, 37.0, 31.5; HRMS
(ES) calcd [M þ Na] for C21H15BrN4NaO3S 504.9946, obsd 504.9934.
4.3.2. (3R)-6-Bromo-8-(1-methyl-1H-[1,2,3]triazol-4-yl)-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (7b)
From 6b (60 mg, 0.116 mmol) was prepared 7b (42 mg, 73%
yield) after puriﬁcation by column chromatography on silica gel
DCM:MeOH:AcOH 91:7:2; [a]D 5 (c 0.10, DMSO); IR 1779, 1693,
1606, 1531, 1307, 1127, 886, 818 cm1; 1H NMR, (400 MHz, d6-
DMSO) d 8.01 (d, J ¼ 7.9 Hz, 1H), 7.92 (d, J ¼ 6.8 Hz, 1H), 7.82e7.73
(m, 2H), 7.59e7.49 (m, 2H), 7.39 (t, J¼ 7.1 Hz,1H), 6.91 (d, J¼ 6.9 Hz,
1H), 5.67 (d, J ¼ 8.8 Hz, 1H), 4.56e4.33 (m, 2H), 3.89 (dd, J ¼ 11.2,
C. Bengtsson et al. / European Journal of Medicinal Chemistry 54 (2012) 637e646 6439.7 Hz,1H), 3.82 (s, 3H), 3.58 (d, J¼ 11.2 Hz,1H); 13C NMR (100MHz,
d6-DMSO) d 169.2, 156.4, 151.4, 149.7, 141.2, 133.2, 132.7, 131.1, 128.6,
126.9, 126.3, 125.8, 125.5, 124.7, 123.8, 123.1, 113.0, 105.4, 64.7, 36.5,
36.3, 31.5; HRMS (ES) calcd [M þ Na] for C22H17BrN4NaO3S
519.0102, obsd 519.0098.
4.3.3. (3R)-6-Bromo-8-(1-ethyl-1H-[1,2,3]triazol-4-yl)-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (7c)
From 6c (88 mg, 0.167 mmol) was prepared 7c (74 mg, 87%
yield) after puriﬁcation by HPLC; [a]D 2 (c 0.10, DMSO); IR 1725,
1617, 1475, 1167, 768, 719 cm1; 1H NMR, (400 MHz, d6-DMSO)
d 8.02e7.96 (m, 1H), 7.96e7.88 (m, 1H), 7.78 (d, J ¼ 8.0 Hz, 1H), 7.67
(s, 1H), 7.58e7.48 (m, 2H), 7.39 (t, J ¼ 7.6 Hz, 1H), 6.92 (d, J ¼ 6.9 Hz,
1H), 5.68 (d, J ¼ 8.9 Hz, 1H), 4.57e4.33 (m, 2H), 4.16e4.06 (m, 2H),
3.88 (dd, J ¼ 11.4, 9.8 Hz, 1H), 3.57 (d, J ¼ 11.4 Hz, 1H), 1.03 (t,
J ¼ 7.1 Hz, 3H); 13C NMR (100 MHz, d6-DMSO) d 169.4, 156.6, 151.6,
149.9, 141.3, 133.4,132.8,131.2, 128.8,127.1, 126.5,126.0,125.7, 124.1,
123.4, 123.2, 113.4, 105.5, 64.9, 44.7, 36.7, 31.7, 15.1; HRMS (ES) calcd
[M þ Na] for C23H19BrN4NaO3S 533.0259, obsd 533.0255.
4.3.4. (3R)-6-Bromo-8-(1-cyclopropylmethyl-1H-[1,2,3]triazol-4-
yl)-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (7d)
From 6d (55 mg, 1 mmol) was prepared 7d (51 mg, 93% yield)
after puriﬁcation by column chromatography on silica gel
DCM:MeOH:AcOH 91:7:2; [a]D 2 (c 0.10, DMSO); IR 1634, 1474,
1396, 1179, 791, 768 cm1; 1H NMR, (400 MHz, d6-DMSO)
d 8.04e7.97 (m, 1H), 7.95e7.89 (m, 1H), 7.79 (d, J ¼ 8.1 Hz, 1H), 7.58
(s, 1H), 7.56e7.49 (m, 2H), 7.40 (t, J ¼ 7.9 Hz, 1H), 6.93 (d, J ¼ 7.0 Hz,
1H), 5.56 (d, J ¼ 8.7 Hz, 1H), 4.55e4.31 (m, 2H), 4.03e3.91 (m, 2H),
3.81 (dd, J¼ 11.4, 9.4 Hz,1H), 3.58 (d, J¼ 11.4 Hz,1H), 0.83e0.71 (m,
1H), 0.20e0.06 (m, 2H), 0.04e0.07 (m, 2H); 13C NMR (100 MHz, d6-
DMSO) d 169.4, 156.7, 150.6, 150.1, 141.4, 133.5, 132.8, 131.2, 128.7,
127.1, 126.5, 126.0, 125.7, 124.0, 123.4, 123.3, 113.5, 105.1, 66.2, 53.7,
37.0, 32.4, 11.0, 3.4 (splitted, 2C); HRMS (ES) calcd [M þ Na] for
C25H21BrN4NaO3S 559.0415, obsd 559.0420.
4.3.5. (3R)-8-(1-Benzyl-1H-[1,2,3]triazol-4-yl)-6-bromo-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (7e)
From 6e (79 mg, 0.135 mmol) was prepared 7e (66 mg, 85%
yield) after puriﬁcation by HPLC; [a]D 11 (c 0.10, DMSO); IR 1750,
1614, 1474, 1201, 714 cm1; 1H NMR, (400 MHz, d6-DMSO)
d 8.04e7.92 (m, 2H), 7.83 (s, 1H), 7.78 (d, J ¼ 8.3 Hz, 1H), 7.61e7.52
(m, 2H), 7.36 (t, J ¼ 7.6 Hz, 1H), 7.17 (t, J ¼ 7.3 Hz, 1H), 7.05 (t,
J ¼ 7.4 Hz, 2H), 6.89 (d, J ¼ 6.9 Hz, 1H), 6.77 (d, J ¼ 7.4 Hz, 2H), 5.68
(d, J ¼ 8.9 Hz, 1H), 5.40 (s, 2H), 4.57e4.32 (m, 2H), 3.89 (t,
J ¼ 10.4 Hz, 1H), 3.59 (d, J ¼ 5.8 Hz, 1H); 13C NMR (100 MHz, d6-
DMSO) d 169.2, 156.4, 151.0, 149.7, 141.3, 135.5, 133.2, 132.2, 131.0,
128.6, 128.5 (2C), 127.8, 126.9, 126.9 (2C), 126.3, 125.9, 125.5, 124.3,
123.6, 123.0, 113.2, 105.2, 64.7, 52.6, 36.8, 31.6; HRMS (ES) calcd
[M þ Na] for C28H21BrN4NaO3S 595.0415, obsd 595.0410.
4.3.6. (3R)-6-Bromo-8-[1-(4-methyl-benzyl)-1H-[1,2,3]triazol-4-
yl]-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (7f)
From 6f (93 mg, 0.153 mmol) was prepared 7f (74 mg, 82% yield)
after puriﬁcation byHPLC; [a]D6 (c 0.10, DMSO); IR 1748,1612,1474,
1199, 1120, 788, 762 cm1; 1H NMR, (400 MHz, d6-DMSO) d 7.99 (t,
J¼ 8.8Hz, 2H), 7.82e7.75 (m, 2H), 7.63e7.53 (m, 2H), 7.37 (t, J¼ 7.7Hz,
1H), 6.89 (d, J¼ 7.1 Hz,1H), 6.83 (d, J¼ 7.8 Hz, 2H), 6.68 (d, J¼ 7.9 Hz,
2H), 5.69 (d, J¼ 8.9 Hz,1H), 5.34 (s, 2H), 4.55e4.31 (m, 2H), 3.89 (dd,
J ¼ 11.9, 9.4 Hz, 1H), 3.60 (d, J ¼ 11.9 Hz, 1H), 2.21 (s, 3H); 13C NMR
(100 MHz, d6-DMSO) d 169.4, 156.6, 151.2, 149.9, 141.5, 137.3, 133.5,132.6, 132.4, 131.2, 129.2 (2C), 128.8, 127.3 (2C), 127.1, 126.5, 126.1,
125.7,124.3,123.8,123.2,113.4,105.4, 64.9, 52.6, 37.0, 31.8, 20.8;HRMS
(ES) calcd [M þ Na] for C29H23BrN4NaO3S 609.0572, obsd 609.0576.
4.3.7. (3R)-6-Bromo-7-naphthalen-8-[1-(4-nitro-benzyl)-1H-
[1,2,3]triazol-4-yl]-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-
a]pyridine-3-carboxylic acid (7g)
From 6g (67 mg, 0.106 mmol) was prepared 7g (41 mg, 63%
yield) after puriﬁcation by HPLC; [a]D 4 (c 0.10, DMSO); IR 1734,
1592, 1521, 1476, 1344, 1160, 1111, 798, 777, 731 cm1; 1H NMR,
(400MHz, d6-DMSO) d 7.99e7.94 (m,1H), 7.93e7.89 (m,1H), 7.88 (s,
1H), 7.83 (d, J ¼ 8.7 Hz, 2H), 7.76 (d, J ¼ 8.2 Hz, 1H), 7.55e7.48 (m,
2H), 7.36 (t, J¼ 7.9 Hz,1H), 6.95 (d, J¼ 8.6 Hz,1H), 6.87 (d, J¼ 7.1 Hz,
1H), 5.69 (dd, J ¼ 7.8, 1.0 Hz, 1H), 5.59 (s, 2H), 4.54e4.31 (m, 2H),
3.91 (dd, J ¼ 11.7, 9.1 Hz, 1H), 3.60 (dd, J ¼ 11.7, 1.0 Hz, 1H); 13C NMR
(100 MHz, d6-DMSO) d 169.4, 156.6, 151.1, 150.0, 147.0, 143.2, 141.8,
133.4, 132.3, 131.1, 128.7, 128.2 (2C), 127.1, 126.5, 126.1, 125.7, 124.8,
123.8 (2C), 123.7, 123.2, 113.4, 105.1, 64.9, 51.9, 37.0, 31.8; HRMS (ES)
calcd [M þ Na] for C28H20BrN5NaO5S 640.0266, obsd 640.0270.
4.3.8. (3R)-8-((S)-1-Benzyl-2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-
yl)-6-bromo-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-
thiazolo[3,2-a]pyridine-3-carboxylic acid (7h)
From 6h (80 mg, 0.126 mmol) was prepared 7h (60 mg, 77%
yield) after puriﬁcation by HPLC; [a]D104 (c 0.10, DMSO); IR 1776,
1622, 1532, 1475, 1308, 1163, 1018, 792, 701 cm1; 1H NMR,
(400 MHz, d6-DMSO) d 8.09e7.99 (m, 1H), 7.97e7.93 (m, 1H),
7.84e7.78 (m, 2H), 7.61e7.52 (m, 2H), 7.43e7.37 (m, 1H), 6.98e6.85
(m, 4H), 6.72e6.67 (m, 2H), 5.67 (d, J ¼ 9.0 Hz, 1H), 4.66e4.24 (m,
3H), 3.94e3.83 (m, 1H), 3.62e3.50 (m, 3H), 3.03e2.89 (m, 1H),
2.80e2.63 (m, 1H); 13C NMR (100 MHz, d6-DMSO) d 169.2 (splitted,
1C), 156.4, 151.2 þ 151.1 (1C), 149.7, 140.9 þ 140.7 (1C), 136.9, 133.3
(splitted, 1C), 132.6 (splitted, 1C), 131.1 (splitted, 1C), 128.6 (splitted,
1C), 128.5 (splitted 2C), 128.1 (2C), 126.8 (splitted, 1C), 126.3þ 126.2
(1C), 125.9 (splitted, 1C), 125.5 (splitted, 1C), 123.8, 123.3, 123.1,
122.9, 113.1 þ 113.0 (1C), 105.6 (splitted, 1C), 64.7 (splitted, 1C),
64.6 þ 64.5 (splitted, 1C), 62.8 þ 62.7 (1C), 36.9, 36.6 þ 36.5
(splitted, 1C), 31.5 þ 31.4 (splitted, 1C); HRMS (ES) calcd [M þ Na]
for C30H25BrN4NaO4S 639.0678, obsd 639.0680.
4.3.9. (3R)-6-Bromo-7-naphthalen-1-ylmethyl-5-oxo-8-[1-(2,3,4-
tri-hydroxy-ß-D-xylopyranosyl)-1H-[1,2,3]triazol-4-yl]-2,3-
dihydro-5H-thiazolo[3,2-a]pyridine-3-carboxylic acid (7i)
From 6i (72mg, 0.095mmol) was prepared 7i (46mg, 79% yield)
after puriﬁcation by HPLC; [a]D 21 (c 0.10, DMSO); IR 3351, 1722,
1621, 1473, 1310, 1039, 991, 792 cm1; 1H NMR, (400 MHz, d6-
DMSO) d 8.09e8.04 (m, 1H), 8.00 (d, J ¼ 15.2 Hz, 1H), 7.96e7.91 (m,
1H), 7.79 (d, J ¼ 8.2 Hz, 1H), 7.59e7.51 (m, 2H), 7.40 (dt, J ¼ 0.7,
7.7 Hz, 1H), 6.94 (d, J ¼ 7.2 Hz, 1H), 5.68 (dd, J ¼ 9.1, 1.1 Hz, 1H), 5.34
(dd, J ¼ 9.2, 1.5 Hz, 1H), 4.54e4.30 (m, 2H), 3.94e3.85 (m, 1H),
3.74e3.66 (m, 1H), 3.61e3.47 (m, 2H), 3.36e3.18 (m, 3H); 13C NMR
(100MHz, d6-DMSO) d 169.2, 156.4, 151.2þ 151.1 (1C), 150.0þ 149.9
(1C), 141.1, 133.3, 132.6, 131.2, 128.6, 126.9, 126.4 þ 126.3 (1C),
125.9 þ 125.9 (1C), 125.6, 123.9, 123.3, 123.1, 113.2 þ 113.1 (1C),
105.3, 88.0 þ 87.9 (1C), 76.9, 71.9 þ 71.8 (1C), 69.0, 68.2 þ 68.1 (1C),
64.7, 36.7 þ 36.6 (1C), 31.5; HRMS (ES) calcd [M þ Na] for
C26H23BrN4NaO7S 637.0369, obsd 637.0357.
4.4. Typical procedure for the dehalogenation of the 8-position
triazole functionalized bicyclic 2-pyridones (compounds 8aei)
4.4.1. (3R)-7-Naphthalen-1-ylmethyl-5-oxo-8-(1H-[1,2,3]triazol-4-
yl)-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-carboxylic acid (8a)
7a(10.1 mg, 0.0209 mmol), ammoniumformate (19.7 mg,
0.313 mmol) and 10% Pd/C (5.0 mg) were dissolved in MeOH (2 ml).
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evaporated. The residue was dissolved in DMSO and Pd/C was
ﬁltered off. Puriﬁcation by HPLC gave8a (6.2 mg, 73%). [a]D 5 (c 0.25,
DMSO); IR 1733, 1634, 1483, 1178, 780 cm1; 1H NMR, (400 MHz,
d6-DMSO) d 8.02 (s,1H, broad), 7.99e7.92 (m,1H), 7.85 (d, J¼ 8.3 Hz,
1H), 7.83e7.78 (m, 1H), 7.56e7.49 (m, 2H), 7.46 (t, J ¼ 7.2 Hz, 1H),
7.29 (d, J ¼ 7.0 Hz, 1H), 5.51e5.42 (m, 2H), 4.34e4.10 (m, 2H), 3.81
(dd, J ¼ 12.0, 9.1 Hz, 1H), 3.50 (dd, J ¼ 12.0, 1.4 Hz, 1H); 13C NMR
(125 MHz, d6-DMSO) d 169.4, 159.7, 158.1 þ 157.8 (1C), 153.7, 149.7,
134.0,133.4,131.3,128.6,127.5,127.4,126.4,125.9,125.6,123.9,113.9
(splitted, 2C), 104.3, 63.1, 35.8, 31.2; HRMS (ES) calcd [M þ Na] for
C21H16N4NaO3S 427.0841, obsd 427.0836.
4.4.2. (3R)-8-(1-Methyl-1H-[1,2,3]triazol-4-yl)-7-naphthalen-1-
ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid (8b)
From 7b (20 mg, 0.040 mmol) was prepared 8b (14 mg, 85%
yield) after puriﬁcation by HPLC; [a]D 3 (c 0.10, DMSO); IR 1734,
1622, 1566, 1492, 1441, 1183, 782 cm1; 1H NMR, (400 MHz, d6-
DMSO) d 8.31 (s, 1H), 7.99e7.92 (m, 1H), 7.86 (d, J ¼ 8.3 Hz, 1H),
7.83e7.75 (m, 1H), 7.56e7.43 (m, 3H), 7.33 (d, J ¼ 6.7 Hz, 1H), 5.44
(d, J ¼ 8.7 Hz, 1H), 5.38 (s, 1H), 4.36e4.10 (m, 2H), 4.07 (s, 3H), 3.79
(dd, J ¼ 11.2, 9.5 Hz, 1H), 3.49 (d, J ¼ 11.2 Hz, 1H); 13C NMR
(100 MHz, d6-DMSO) d 169.4, 159.7, 153.9, 149.6, 141.2, 134.0, 133.4,
131.4, 128.6, 127.8, 127.4, 126.3, 125.8, 125.6, 125.2, 123.9, 113.6,
104.5, 63.1, 36.4, 35.8, 31.2; HRMS (ES) calcd [M þ Na] for
C22H18N4NaO3S 441.0997, obsd 441.1003.
4.4.3. (3R)-8-(1-Ethyl-1H-[1,2,3]triazol-4-yl)-7-naphthalen-1-
ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid (8c)
From 7c (38mg, 0.075mmol)was prepared 8c (22mg, 69% yield)
after puriﬁcation by HPLC; [a]D 11 (c 0.10, DMSO); IR 1731, 1627,
1563,1491,1443,1220,1197,1168, 781 cm1; 1HNMR, (400MHz, d6-
DMSO) d 8.32 (s, 1H), 7.97e7.92 (m, 1H), 7.85 (d, J ¼ 8.3 Hz, 1H),
7.83e7.78 (m,1H), 7.54e7.48 (m, 2H), 7.46 (t, J¼ 7.9 Hz, 1H), 7.30 (d,
J¼ 7.0 Hz, 1H), 5.46e5.41 (m, 2H), 4.38 (q, J¼ 7.3 Hz, 2H), 4.35e4.12
(m, 2H), 3.78 (dd, J¼ 11.8, 9.4 Hz,1H), 3.49 (d, J¼ 11.8 Hz,1H),1.38 (t,
J ¼ 7.3 Hz, 3H); 13C NMR (100 MHz, d6-DMSO) d 169.5, 159.7, 153.7,
149.6,141.2,134.0,133.4,131.4,128.6,127.7,127.4,126.3,125.8,125.6,
123.9, 123.7, 113.8, 104.6, 63.1, 44.7, 35.7, 31.3, 15.2; HRMS (ES) calcd
[M þ Na] for C23H20N4NaO3S 455.1154, obsd 455.1148.
4.4.4. (3R)-8-(1-Cyclopropylmethyl-1H-[1,2,3]triazol-4-yl)-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (8d)
From 7d (44 mg, 0.082 mmol) was prepared 8d (26 mg, 72%
yield) after puriﬁcation by HPLC; [a]D 9 (c 0.10, DMSO); IR 1731,
1621, 1489, 1444, 1197, 1167, 782 cm1; 1H NMR, (400 MHz, d6-
DMSO) d 8.28 (s, 1H), 7.97e7.92 (m, 1H), 7.88e7.80 (m, 2H),
7.54e7.49 (m, 2H), 7.47 (t, J ¼ 7.2 Hz, 1H), 7.29 (d, J ¼ 7.0 Hz, 1H),
5.50 (s, 1H), 5.46 (dd, J ¼ 8.8, 1.2 Hz, 1H), 4.37e4.14 (m, 2H), 4.22 (d,
J ¼ 7.2 Hz, 2H), 3.80 (dd, J ¼ 11.9, 9.3 Hz, 1H), 3.50 (dd, J ¼ 11.9,
1.1 Hz, 1H), 1.25e1.13 (m, 1H), 0.50e0.44 (m, 2H), 0.36e0.31 (m,
2H); 13C NMR (100MHz, d6-DMSO) d 169.5,159.7, 153.6,149.6,141.1,
134.1, 133.4, 131.3, 128.6, 127.5, 127.4, 126.3, 125.8, 125.6, 123.8 (2C),
113.9, 104.6, 63.0, 53.8, 35.8, 31.2, 11.2, 3.6 (splitted, 2C); HRMS (ES)
calcd [M þ Na] for C25H22N4NaO3S 481.1310, obsd 481.1319.
4.4.5. (3R)-8-(1-Benzyl-1H-[1,2,3]triazol-4-yl)-7-naphthalen-1-
ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid methyl ester (8e)
From 7e (34 mg, 0.059 mmol) was prepared 8e (20 mg, 67%
yield) after puriﬁcation by HPLC; [a]D 4 (c 0.10, DMSO); IR 1723,
1615, 1488, 1442, 1158, 718 cm1; 1H NMR, (400 MHz, d6-DMSO)d 8.41 (s, 1H), 7.98e7.93 (m, 1H), 7.87e7.79 (m, 2H), 7.55e7.47 (m,
2H), 7.46e7.39 (m, 1H), 7.33e7.24 (m, 4H), 7.21e7.16 (m, 2H), 5.62
(s, 2H), 5.49 (s, 1H), 5.45 (dd, J ¼ 8.9, 1.4 Hz, 1H), 4.38e4.13 (m, 2H),
3.79 (dd, J ¼ 9.2, 2.7 Hz, 1H), 3.49 (dd, J ¼ 11.9, 1.4 Hz, 1H); 13C NMR
(100 MHz, d6-DMSO) d 169.4, 159.7, 153.5, 149.7, 141.4, 135.9, 133.9,
133.4, 131.3, 128.7 (2C), 128.6, 128.0, 127.5 (2C), 127.5, 127.4, 126.3,
125.8, 125.6, 124.6, 123.8, 113.9, 104.4, 63.0, 52.9, 35.7, 31.2; HRMS
(ES) calcd [M þ Na] for C28H22N4NaO3S 517.1310, obsd 517.1303.
4.4.6. (3R)-8-[1-(4-Methyl-benzyl)-1H-[1,2,3]triazol-4-yl]-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (8f)
From 7f (31mg, 0.053mmol) was prepared 8f (25mg, 92% yield)
after puriﬁcation by HPLC; [a]D 3 (c 0.10, DMSO); IR 1727, 1621,
1563, 1488, 1442, 1158, 783 cm1; 1H NMR, (400 MHz, d6-DMSO)
d8.36 (s,1H), 7.95 (d, J¼7.9Hz,1H), 7.88e7.78 (m, 2H), 7.56e7.47 (m,
2H), 7.42 (t, J¼7.6Hz,1H), 7.29e7.23 (m,1H), 7.10 (s, 4H), 5.55 (s, 2H),
5.48 (s,1H), 5.45 (d, J¼ 8.9 Hz,1H), 4.36e4.11 (m, 2H), 3.83e3.74 (m,
1H), 3.49 (d, J ¼ 11.8 Hz, 1H), 2.26 (s, 3H); 13C NMR (100 MHz, d6-
DMSO) d 169.4, 159.7, 153.5, 149.6, 141.4, 137.4, 134.0, 133.4, 132.9,
131.3, 129.2 (2C), 128.6, 127.6 (2C), 127.5, 127.4, 126.3, 125.8, 125.6,
124.5,123.8,113.9,104.5, 63.0, 52.7, 35.7, 31.2, 20.7; HRMS (ES) calcd
[M þ Na] for C29H24N4NaO3S 531.1467, obsd 531.1463.
4.4.7. (3R)-8-[1-(4-Amino-benzyl)-1H-[1,2,3]triazol-4-yl]-7-
naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (8g)
From 7g (32 mg, 0.052 mmol) was prepared 8g (22 mg, 82%
yield) after puriﬁcation by HPLC; [a]D 11 (c 0.10, DMSO); IR 1681,
1622, 1490, 1444, 1198 cm1; 1H NMR, (400 MHz, d6-DMSO) d 8.34
(s, 1H), 7.98e7.93 (m, 1H), 7.88e7.78 (m, 2H), 7.55e7.47 (m, 2H),
7.46e7.40 (m, 11H), 7.27 (d, J ¼ 7.0 Hz, 1H), 7.11 (d, J ¼ 8.4 Hz, 2H),
6.83 (d, J ¼ 8.3 Hz, 2H), 5.49 (s, 2H), 5.47e5.42 (m, 2H), 4.36e4.12
(m, 2H), 3.78 (dd, J ¼ 11.9, 9.2 Hz, 1H), 3.48 (dd, J ¼ 11.9, 1.4 Hz,
1H); 13C NMR (100MHz, d6-DMSO) d 169.4, 159.7, 153.6, 149.6, 141.6
(broad),141.4, 134.0, 133.4, 131.3, 129.0 (2C), 128.6, 128.1
(broad),127.6, 127.4, 126.3, 125.8, 125.6, 124.3, 123.9, 117.8 (2C),
113.9, 104.5, 63.0, 52.7, 35.7, 31.2; HRMS (ES) calcd [M þ Na] for
C28H23N5NaO3S 532.1419, obsd 532.1409.
4.4.8. (3R)-8-((S)-1-Benzyl-2-hydroxy-ethyl)-1H-[1,2,3]triazol-4-
yl)-7-naphthalen-1-ylmethyl-5-oxo-2,3-dihydro-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (8h)
From 7h (34 mg, 0.056 mmol) was prepared 8h (27 mg, 88%
yield) after puriﬁcation by HPLC; [a]D 154 (c 0.10, DMSO); IR 1731,
1645, 1489, 1439, 1196, 1022, 996, 782, 700 cm1; 1H NMR,
(400 MHz, d6-DMSO) d 8.35 (d, J ¼ 16.4 Hz, 1H), 8.00e7.95 (m, 1H),
7.89 (d, J¼ 8.2 Hz,1H), 7.81e7.71 (m,1H), 7.57e7.46 (m, 3H), 7.33 (d,
J ¼ 6.9 Hz, 1H), 7.15e6.97 (m, 5H), 5.47e5.41 (m, 1H), 5.33 (d,
J ¼ 14.5 Hz, 1H), 4.90e4.79 (m, 1H), 4.28e3.94 (m, 3H), 3.92e3.83
(m, 2H), 3.83e3.75 (m, 1H), 3.53e3.47 (m, 1H), 3.27e3.18 (m, 1H),
3.14e3.04 (m, 1H); 13C NMR (100 MHz, d6-DMSO) d 169.5, 159.7,
153.9 þ 153.8 (1C), 149.5 (splitted, 1C), 140.6 þ 140.5 (1C),
137.2 þ 137.1 (1C), 134.0 (splitted, 1C), 133.5, 131.4 þ 131.3 (1C),
128.8 (splitted, 2C), 128.6, 128.2 (2C), 127.9 þ 127.8 (1C), 127.5
(splitted, 1C), 126.3 (splitted, 2C), 125.8, 125.7, 124.0 (splitted, 1C),
124.0 þ 123.7 (1C), 113.5 þ 113.4 (1C), 104.6, 64.8 (splitted, 1C), 63.1
(splitted, 1C), 63.0, 37.1 þ 37.0 (1C), 35.8 (splitted, 1C), 31.2; HRMS
(ES) calcd [M þ Na] for C30H26N4NaO4S 561.1572, obsd 561.1580.
4.4.9. (3R)-7-Naphthalen-1-ylmethyl-5-oxo-8-[1-(2,3,4-tri-
hydroxy-ß-D-xylopyranosyl)-1H-[1,2,3]triazol-4-yl]-2,3-dihydro-
5H-thiazolo[3,2-a]pyridine-3-carboxylic acid (8i)
From 7i (38mg, 0.062mmol) was prepared 8i (24mg, 74% yield)
after puriﬁcation by HPLC; [a]D 22 (c 0.10, DMSO); IR 1716, 1633,
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(broad s, 1H) 8.66 (d, J ¼ 4.0 Hz, 1H), 7.99e7.94 (m, 1H), 7.88 (d,
J ¼ 8.1 Hz, 1H), 7.81e7.76 (m, 1H), 7.55e7.46 (m, 3H), 7.37 (d,
J ¼ 6.7 Hz, 1H), 5.56 (d, J ¼ 9.2 Hz, 1H), 5.43 (d, J ¼ 8.5 Hz, 1H), 5.26
(d, J ¼ 10.0 Hz, 1H), 4.36 (d, J ¼ 17.3 Hz, 1H), 4.16e4.07 (m, 1H),
3.90e3.74 (m, 3H), 3.53e3.45 (m, 2H), 3.43e3.33 (m, 2H); 13C NMR
(100 MHz, d6-DMSO) d 169.4, 159.6, 153.8 þ 153.7 (1C), 149.7, 141.1
(splitted, 1C), 133.9 (splitted, 1C), 133.5, 131.5 þ 131.4 (1C), 128.6,
128.2 þ 128.1 (1C), 127.6, 126.4, 125.8, 125.7, 124.1 þ 124.0 (1C),
123.5 (split, 1C), 113.4 þ 113.3 (1C), 104.4 þ 104.3 (1C), 88.4 (split,
1C), 77.0 (split, 1C), 72.50þ 71.9 (1C), 69.1, 68.3, 62.9 (split, 1C), 35.9,
31.2 (split, 1C); HRMS (ES) calcd [M þ Na] for C26H24N4NaO7S
559.1263, obsd 559.1250.
4.4.10. Methyl 8-cyclopropyl-2-(1-methyl-1H-1,2,3-triazol-4-yl)-7-
(naphthalen-1-ylmethyl)-5-oxo-5H-thiazolo[3,2-a]pyridine-3-
carboxylate (10)
NaN3 (0.72 mmol, 47 mg), Iodomethane (0.18 mmol, 11 ml),
CuSO4 (0.018 mmol, 3 mg) and Na-ascorbate (0.054 mmol, 11 mg)
were dissolved in DMSO:H2O 1:1 (1ml) and heated to 80 Cwith an
oil bath for 5 min. 9 (0.12 mmol, 50 mg) dissolved in DMSO (1 ml)
was added and the reaction was stirred for 1 h. The reaction
mixture was diluted with saturated NaHCO3 (aq) and extracted
with DCM, the organic phase was dried (Na2SO4), ﬁltered and
concentrated. The crude reaction mixture was puriﬁed by column
chromatography on silica gel (heptane:EtOAc 50:50/ 20:80). To
give 10 (40 mg, 71%) IR l 1734, 1654, 1560, 1466 cm1; 1H NMR
(400 MHz, d6-DMSO) d 8.34 (s, 1H), 8.03e7.94 (m, 1H), 7.94e7.84
(m, 2H), 7.58e7.45 (m, 3H), 7.41e7.34 (m, 1H), 5.55 (s, 1H), 4.58
(s, 2H), 4.14 (s, 3H), 3.85 (s, 3H), 1.99e1.89 (m, 1H), 1.12e0.99 (m,
2H), 0.89e0.78 (m, 2H) 13C NMR (100MHz, d6-DMSO) d 160.7,157.5,
154.3, 145.3, 135.4, 134.5, 133.5, 131.5, 128.6, 127.5, 127.4, 126.4,
125.8, 125.7, 124.0, 123.9, 123.8, 119.9, 111.9, 109.9, 53.3, 36.8, 35.4,
10.6, 7.5 (2C).
4.4.11. 8-Cyclopropyl-2-(1-methyl-1H-1,2,3-triazol-4-yl)-7-
(naphthalen-1-ylmethyl)-5H-thiazolo[3,2-a]pyridin-5-one (11)
IR l 1637, 1558, 1472 cm1; 1H NMR (500 MHz, d4-AcOH)
d 8.73e8.71 (m, 1H), 8.37e8.34 (m, 1H) 7.95e7.89 (m, 2H),
7.85e7.81 (m,1H), 7.52e7.43 (m, 3H), 7.31e7.27 (m,1H), 6.16 (s, 1H),
4.69 (s, 2H), 4.21 (s, 3H), 2.00e1.92 (m, 1H), 1.16e1.11 (m, 2H),
0.92e0.88 (m, 2H) 13C NMR (125 MHz, d4-AcOH) d 160.3, 155.9,
149.2, 139.2, 135.6, 135.2, 133.0, 129.8, 128.6, 128.4, 127.3, 126.8,
126.6, 124.7, 124.3, 122.9, 121.8, 116.5, 111.0, 37.6, 37.0, 11.8, 8.3 (2C).
4.5. Typical procedure for the Huisgen 1,3-dipolar cycloaddition,
followed by TMSE deprotection, in the 2-position of the bicyclic 2-
pyridones (compounds 13aef)
4.5.1. 8-Cyclopropyl-2-(1-methyl-1H-1,2,3-triazol-4-yl)-7-
(naphthalen-1-ylmethyl)-5-oxo-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid (13b)
NaN3 (1.56 mmol, 101 mg), CuSO4 (0.05 mmol, 8 mg), Na-
ascorbate (0.12 mmol, 24 mg) and methyliodide (0.39 mmol,
36 ml) were dissolved in DMSO:H2O 9:1 (5 ml) and stirred at rt for
10 min. 12a (0.26 mmol, 130 mg) was added and the reaction was
stirred at rt for 18 h. The reaction mixture was diluted with water
and pH was set to approx 8 with saturated NaHCO3 (aq) and
extracted with EtOAc. The organic phase was dried (Na2SO4),
ﬁltered and concentrated. The crude material was dissolved in THF
(5 ml) and TBAF$3H2O (0.31 mmol, 98 mg) was added and the
reaction was stirred at rt for 3 h. The reaction mixture was diluted
with water and pH was set to approx 1 with 1 M HCl (aq), and then
extracted with EtOAc. The organic phase was dried (Na2SO4),
ﬁltered and concentrated, the crude product was puriﬁed by HPLC.The product was freeze dried, to give 13b (82 mg, 69%) IR l 1717,
1636, 1558, 1472 cm1; 1H NMR (400 MHz, d6-DMSO) d 8.37 (s, 1H),
7.99e7.93 (m, 1H), 7.93e7.85 (m, 2H), 7.55e7.45 (m, 3H), 7.40e7.35
(m, 1H), 5.53 (s, 1H), 4.57 (s, 2H), 4.14 (s, 3H), 1.95e1.86 (m, 1H),
1.08e1.01 (m, 2H), 0.83e0.76 (m, 2H) 13C NMR (100 MHz, d6-
DMSO) d 161.4, 157.6, 153.9, 145.6, 136.0, 134.6, 133.5, 131.5, 128.6,
127.6, 127.4, 126.8, 126.4, 125.8, 125.7, 124.0, 123.8, 117.9, 111.5, 110.0,
36.8, 35.4, 10.6, 7.6 (2C) HRMS (ES) calcd [M þ Na] for
C25H20N4NaO3S 479.1154, obsd 479.1156.
4.5.2. 8-Cyclopropyl-7-(naphthalen-1-ylmethyl)-5-oxo-2-(1H-
1,2,3-triazol-4-yl)-5H-thiazolo[3,2-a]pyridine-3-carboxylic acid
(13a)
From 12a (100 mg, 0.2 mmol) was prepared 13a (50 mg, 56%
yield) after puriﬁcation by HPLC; IR l 1716, 1636, 1464 cm1; 1H
NMR (400 MHz, d6-DMSO) d 8.18 (s, 1H), 8.00e7.94 (m, 1H),
7.94e7.86 (m, 2H), 7.56e7.46 (m, 3H), 7.40e7.36 (m, 1H), 5.52 (s,
1H9), 4.58 (s, 2H), 1.96e1.87 (m, 1H), 1.08e0.99 (m, 2H), 0.84e0.76
(m, 2H) 13C NMR (100 MHz, d6-DMSO) d 161.6, 157.6, 153.8, 145.8,
136.0 (br), 134.6, 133.5, 131.5, 128.6, 128.3 (br), 127.5, 127.4, 126.4,
126.2 (br), 125.8, 125.7, 124.0, 116.8 (br), 111.4, 110.0, 35.4, 10.6, 7.6
(2C) HRMS (ES) calcd [M þ Na] for C24H18N4NaO3S 465.0997, obsd
465.0995.
4.5.3. 2-(1-Benzyl-1H-1,2,3-triazol-4-yl)-8-cyclopropyl-7-
(naphthalen-1-ylmethyl)-5-oxo-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid (13c)
From 12a (100 mg, 0.2 mmol) was prepared 13c (58 mg, 54%
yield) after puriﬁcation by HPLC; IR l 1716, 1634, 1616, 1551, 1471,
1414 cm1; 1H NMR (400 MHz, d6-DMSO) d 8.53 (s, 1H), 8.00e7.94
(m, 1H), 7.94e7.86 (m, 2H), 7.56e7.46 (m, 3H), 7.41e7.29 (m, 6H),
5.71 (s, 2H), 5.51 (s, 1H), 4.58 (s, 2H), 1.97e1.88 (m, 1H), 1.10e1.02
(m, 2H), 0.85e0.77 (m, 2H) 13C NMR (100 MHz, d6-DMSO) d 161.4
(br), 157.6, 153.8, 145.7, 136.3, 135.5, 134.6, 133.5, 131.5, 128.8 (2C),
128.6, 128.3, 128.1 (2C), 127.6, 127.5 (br), 127.3, 126.4, 125.8, 125.7,
124.0, 123.0, 117.4 (br), 111.4, 109.9, 53.2, 35.4, 10.6, 7.6 (2C) HRMS
(ES) calcd [M þ Na] for C31H24N4NaO3S 555.1467, obsd 555.1470.
4.5.4. 7-(naphthalen-1-ylmethyl)-5-oxo-2-(1H-1,2,3-triazol-4-yl)-
8-(3-(triﬂuoromethyl)phenyl)-5H-thiazolo[3,2-a]pyridine-3-
carboxylic acid (13d)
From 12b (121 mg, 0.2 mmol) was prepared 13d (68 mg, 61%
yield) after puriﬁcation by HPLC; IR l 1718, 1636, 1472, 1335 cm1;
1H NMR (400 MHz, d6-DMSO) d 8.20 (s, 1H), 7.93e7.87 (m, 1H),
7.86e7.68 (m, 6H), 7.51e7.37 (m, 3H), 7.29e7.24 (m, 1H), 5.87 (s,
1H), 4.16 (s, 2H) 13C NMR (100 MHz, d6-DMSO) d 161.4, 157.7, 150.8,
146.2, 136.6, 135.8 (br), 134.3, 134.1, 133.3, 131.2, 130.6, 130.1 (q,
J ¼ 31 Hz, 1C), 129.0 (br), 128.5, 127.5, 127.3, 126.8 (br), 126.2, 125.7,
125.6e125.2 (m, 3C), 123.9 (q, J¼ 271Hz, 1C), 123.7, 116.1 (br), 112.5,
110.4, 35.8; HRMS (ES) calcd [M þ Na] for C28H17F3N4NaO3S
569.0871, obsd 569.0873.
4.5.5. 2-(1-Methyl-1H-1,2,3-triazol-4-yl)-7-(naphthalen-1-
ylmethyl)-5-oxo-8-(3-(triﬂuoromethyl)phenyl)-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (13e)
From 12b (121 mg, 0.2 mmol) was prepared 13e (68 mg, 61%
yield) after puriﬁcation by HPLC; IR l 1748, 1616, 1540, 1466,
1335 cm1; 1H NMR (400 MHz, d6-DMSO) d 8.42 (s, 1H), 7.93e7.88
(m, 1H), 7.86e7.69 (m, 6H), 7.51e7.38 (m, 3H), 7.30e7.25 (m, 1H),
5.88 (s, 1H), 4.17 (s, 2H), 4.09 (s, 3H) 13C NMR (100 MHz, d6-DMSO)
d 161.3, 157.7, 150.8, 146.1, 136.6, 135.8, 134.3, 134.1, 133.3, 131.2,
130.6, 130.1 (q, J ¼ 31Hz, 1C), 128.5, 127.8 (br), 127.6, 127.3, 126.8 (q,
J ¼ 4Hz, 1C), 126.2, 125.7, 125.5, 125.4 (q, J ¼ 4Hz, 1C), 123.9 (q,
J ¼ 272Hz, 1C), 123.8, 123.7, 117.0, 112.6, 110.4, 36.8, 35.8 HRMS (ES)
calcd [M þ Na] for C29H19F3N4NaO3S 583.1028, obsd 583.1036.
C. Bengtsson et al. / European Journal of Medicinal Chemistry 54 (2012) 637e6466464.5.6. 2-(1-Benzyl-1H-1,2,3-triazol-4-yl)-7-(naphthalen-1-
ylmethyl)-5-oxo-8-(3-(triﬂuoromethyl)phenyl)-5H-thiazolo[3,2-a]
pyridine-3-carboxylic acid (13f)
From 12b (121 mg, 0.2 mmol) was prepared 13f (70 mg, 55%
yield) after puriﬁcation by HPLC; IR l 1718, 1637, 1472, 1430,
1334 cm1; 1H NMR (400 MHz, d6-DMSO) d 8.55 (s, 1H), 7.93e7.87
(m, 1H), 7.86e7.68 (m, 6H), 7.50e7.37 (m, 3H), 7.37e7.24 (m, 6H),
5.88 (s, 1H), 5.68 (s, 2H), 4.17 (s, 2H), 13C NMR (100 MHz, d6-DMSO)
d 161.2, 157.7, 150.9, 146.0, 136.5, 136.0, 135.4, 134.3, 134.1, 133.3,
131.2, 130.6, 130.1 (q, J ¼ 32Hz, 1C), 128.8 (2C), 128.5, 128.3, 128.1
(2C), 127.6, 127.4 (br), 127.3, 126.8 (q, J¼ 3Hz, 1C), 126.2, 125.7, 125.5
(splitted, 2C), 123.9 (q, J¼ 272Hz, 1C), 123.7, 123.1, 117.3, 112.7, 110.4,
53.2, 35.8 HRMS (ES) calcd [MþNa] for C35H23F3N4NaO3S 659.1341,
obsd 659.1346.
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